PFHxA

PFHxA enters U.S. drinking water through four overlapping pathways: (1) industrial discharge and atmospheric deposition from fluoropolymer and fluorochemical manufacturing — the North Carolina Cape Fear River cluster (Pittsboro, Harnett County, Holly Springs, Coats, Lillington, Linden and Fuquay-Varina, all measuring a uniform 60.4 ppt) is downstream of the Chemours Fayetteville Works plume, and the Oakdale, MN system (96 of 193 tests positive at 33.4 ppt) draws from the well-documented 3M Cottage Grove groundwater plume; (2) AFFF firefighting-foam release at military installations and civilian airports — small isolated systems with the highest measured PFHxA averages (Sunny Gables, ME at 143.7 ppt; Towns Mobile Home Park, WA at 132.0 ppt; Friendly Acres, CA at 97.4 ppt; Pine Terrace, WA at 85.6 ppt) almost always trace to local AFFF release patterns; (3) environmental biotransformation of 6:2 fluorotelomer precursors used in stain-, grease-, and water-resistant coatings on textiles, paper, and food packaging — 6:2 telomer-based replacement chemistries degrade preferentially to PFHxA, which explains the broad diffuse baseline detection across California, Texas, Florida, and the northeastern manufacturing corridor; and (4) regional industrial legacy at sites like Gadsden Water Works, AL (39 of 42 tests positive at 26.4 ppt over the Etowah County metals-finishing district).

EPA's 2023 IRIS toxicological review identifies developmental effects — specifically reduced fetal growth and offspring body weight — as the dose-defining endpoint for PFHxA, yielding a chronic Reference Dose of 5×10⁻⁴ mg/kg/day. USGS uses that RfD to derive a Health-Based Screening Level of 3,000 ng/L (3 µg/L). Commonly listed PFHxA health concerns — cancer, immune system damage, hormone disruption, fetal/developmental harm, and liver damage — span both the IRIS-derived developmental endpoint of record and class-extrapolated concerns shared across the PFAS family. PFHxA has not been classified as a carcinogen by IARC or NTP. PFHxA is not in the 2024 NPDWR Hazard Index mixture (the Hazard Index covers PFHxS, PFNA, PFBS, and HFPO-DA) and has no individual federal MCL. The much shorter ~30-day human serum half-life relative to long-chain PFCAs is the principal reason PFHxA risk framing sits at the part-per-trillion thousand-level rather than the ppt single-digit level applied to PFOA, PFDA, or HFPO-DA.

PFHxA is one of the more difficult UCMR 5 PFAS to remove cost-effectively with granular activated carbon: short-chain PFCAs adsorb only weakly onto GAC media and break through far earlier than long-chain PFOA, PFDA, or PFOS at comparable loading rates. Anion exchange resin and high-pressure membranes (reverse osmosis, nanofiltration) substantially outperform GAC for PFHxA and should be the lead technology when PFHxA reduction is a primary design target — though for most U.S. utilities PFHxA is detected well below the IRIS-derived health benchmark and treatment economics rarely justify retrofitting for PFHxA alone. Conventional treatment processes — coagulation, sand filtration, disinfection, UV, and ozonation — do not remove PFHxA. Boiling concentrates rather than removes it. NSF/ANSI 53 and NSF P473 certify point-of-use filters for general PFAS reduction; NSF/ANSI 58 covers RO systems. Because PFHxA is not in the federal NPDWR Hazard Index and reported U.S. detections sit well below the IRIS-derived screening range, utilities sizing GAC, anion exchange, or RO for the NPDWR-regulated long-chain PFAS will incidentally control PFHxA at the same time (though with shorter media life than the long-chain compounds drive on their own).